{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 454958463
| IUPAC_name = 4-<nowiki/>{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
| image = Tedatioxetine.svg
| width = 175
| image2 = File:Tedatioxetine ball-and-stick model.png
| width2 = 250

<!--Clinical data-->
| tradename = 
| pregnancy_category = 
| legal_status = Investigational
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 508233-95-2
| ATC_prefix = none
| ATC_suffix = 
| KEGG = D10170
| KEGG_Ref = {{keggcite|changed|kegg}}
| synonyms = Lu AA24530; Lu-AA-24530

<!--Chemical data-->
| C=18 | H=21 | N=1 | S=1 
| molecular_weight = 283.43 g/mol
| smiles = CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
| PubChem = 9878913
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8054590
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = CVASBKDYSQKLSO-UHFFFAOYSA-N
}}

'''Tedatioxetine''' ('''Lu AA24530''') is an [[antidepressant]] that was discovered by scientists at [[Lundbeck]]; in 2007 Lundbeck and [[Takeda Pharmaceutical Company|Takeda]] entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, [[vortioxetine]].<ref>Daniel Beaulieu for First Word Pharma. September 5th, 2007 [http://www.firstwordpharma.com/node/88051?tsid=17#axzz3xkIEA5eH  Lundbeck, Takeda enter strategic alliance for mood disorder, anxiety drugs]</ref>

Tedatioxetine is reported to act as a [[triple reuptake inhibitor]] ([[Serotonin|5-HT]] > [[Norepinephrine|NE]] > [[Dopamine|DA]]) and [[5-HT2A receptor|5-HT<sub>2A</sub>]], [[5-HT2C receptor|5-HT<sub>2C</sub>]], [[5-HT3 receptor|5-HT<sub>3</sub>]] and [[Alpha-1A adrenergic receptor|Î±<sub>1A</sub>-adrenergic receptor]] [[receptor antagonist|antagonist]].<ref name="urlUSPTO20100144788">{{cite web | url = https://www.google.com/patents/US20100144788 | title = Patent US20100144788 - 4- [2- (4-methylphenylsulfanyd-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of adhd, melancholia, treatment resistant depression or residual symptoms in depression | format = | work = | accessdate = 7 April 2014}}</ref><ref name="Stahl2008">{{cite book | author = Stephen M. Stahl | title = Depression and bipolar disorder: Stahl's essential psychopharmacology | url = https://books.google.com/books?id=zqvVZOea2JAC&pg=PA206 | accessdate = 22 November 2011 | date = 19 May 2008 | publisher = Cambridge University Press | isbn = 978-0-521-88663-5 | pages = 206}}</ref><ref name="Stolerman2010">{{cite book | author = Ian P. Stolerman | title = Encyclopedia of Psychopharmacology | url = https://books.google.com/books?id=qoyYobgX0uwC&pg=PA105 | accessdate = 22 November 2011 | date = 30 August 2010 | publisher = Springer | isbn = 978-3-540-68698-9 | pages = 105}}</ref><ref name=Fierce>{{cite web | url = http://www.fiercebiotech.com/press-releases/lu-aa24530-shows-positive-results-major-depressive-disorder-phase-ii-study | title = Lu AA24530 shows positive results in major depressive disorder phase II study - FierceBiotech | format = | work = | accessdate = }}</ref> 

As of 2009, it was in [[Phases of clinical research#Phase II|phase II]] [[clinical trial]]s for [[major depressive disorder]],<ref name=Fierce /> but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.<ref name="urlPipeline of Lundbeck">{{cite web | url = http://investor.lundbeck.com/pipeline.cfm | title = Pipeline of Lundbeck | format = | work = | accessdate = 25 August 2013 }}</ref><ref>UK Medicines Information [http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=4990 Tedatioxetine entry in UKMI].  Page accessed January 20, 2016</ref>

On May 10, 2016, all work on tedatioxetine stopped.<ref>{{Cite web|url=http://adisinsight.springer.com/drugs/800023694|title=Tedatioxetine - AdisInsight|website=adisinsight.springer.com|access-date=2016-06-09}}</ref>

==See also==
* [[MIN-117]]
* [[TGBA01AD]]
* [[Vilazodone]]
* [[Vortioxetine]]

==References==
{{Reflist|2}}

==External links==
* [http://hugin.info/130085/R/1326803/312416.pdf Lu AA24530 shows positive results in major depressive disorder phase II study]

{{Antidepressants}}
{{Adrenergic receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}

[[Category:Antidepressants]]
[[Category:Piperidines]]
[[Category:Thioethers]]
[[Category:Abandoned drugs]]


{{nervous-system-drug-stub}}